Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere, Table of Contents Tierarztl Prax Ausg G Grosstiere Nutztiere 2010; 38(S 01): S45-S49DOI: 10.1055/s-0038-1623051 Ausgewählter Kongressbeitrag Schattauer GmbH Pharmakotherapie der atopischen Dermatitis – aktueller Stand und neue Entwicklungen W. Bäumer 1 Institut für Pharmakologie, Toxikologie und Pharmazie (Leiter: Prof. Dr. W. Löscher) der Stiftung Tierärztliche Hochschule Hannover , M. Kietzmann 1 Institut für Pharmakologie, Toxikologie und Pharmazie (Leiter: Prof. Dr. W. Löscher) der Stiftung Tierärztliche Hochschule Hannover › Author Affiliations Recommend Article Abstract Buy Article Full Text References Literatur 1 Bäumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007; 6: 17-26. 2 Bäumer W, Kietzmann M. Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes. Vet Dermatol 2007; 18: 107-114. 3 Bensignor E, Morgan DM, Nuttall T. Efficacy of an essential fatty acidenriched diet in managing canine atopic dermatitis: a randomized, single-blinded, cross-over study. Vet Dermatol 2008; 19: 156-162. 4 Ferrer L, Alberola J, Queralt M, Brazis P, Rabanal R, Llenas J, Puigdemont A. Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis. Vet Rec 1999; 145: 191-194. 5 Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol 2001; 81: 147-151. 6 Kohno T, Tsuji T, Hirayama K, Watabe K, Matsumoto A, Kohno T, Fujita T. A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice. Biol Pharm Bull 2004; 27: 1392-1396. 7 Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, Rème C. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol 2009; 20: 191-198. 8 Olivry T, Mueller RS. Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003; 14: 121-146. 9 Olivry T, Hill P. The ACVD task force on canine atopic dermatitis (XVIII): histopathology of skin lesions. Vet Immunol Immunopathol 2001; 81: 305-309. 10 Piekutowska A, Pin D, Reme CA, Gatto H, Haftek M. Effects of a topically applied preparation of epidermal lipids on the stratum corneum barrier of atopic dogs. J Comp Pathol 2008; 138: 197-203. 11 Reines I, Kietzmann M, Mischke R, Tschernig T, Lüth A, Kleuser B, Bäumer W. Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol 2009; 129: 1954-1962. 12 Reiter L, Torres S, Wertz P. Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls. Vet Dermatol 2009; 20: 260-266. 13 Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, Kietzmann M, Bäumer W. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009; 18: 57-63. 14 Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nature Rev Drug Discov 2008; 7: 41-53.
